 The FDA has extended the review period of TG Therapeutics Incs NASDAQ: TGTX biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq umbralisib for chronic lymphocytic leukemia CLL and small lymphocytic lymphoma . 